

## **AtheroGenics Names Robert P. Ryan, Ph.D. as Vice President of Regulatory Affairs**

**Atlanta, GA.** - March 25, 2004 - AtheroGenics, Inc. (Nasdaq: AGIX), a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, today announced the appointment of Robert P. Ryan, Ph.D., D.A.B.T., as Vice President of Regulatory Affairs. Dr. Ryan joins AtheroGenics from Quintiles, Inc., where he held the position of Executive Director, Regulatory and Technical Services.

"Robert will oversee all aspects of the company's regulatory operations, playing an integral role in the advancement of AtheroGenics' products, including AGI-1067 and AGIX-4207," said Rob Scott, M.D., Senior Vice President of Clinical Development and Regulatory Affairs and Chief Medical Officer of AtheroGenics. "Robert brings considerable industry experience to AtheroGenics, and his extensive background in a variety of regulatory affairs capacities will allow him to serve as the ideal strategic liaison with the FDA."

In his previous position with Quintiles, Inc., Dr. Ryan served as the company's senior regulatory professional, acting as liaison with the U.S. Food and Drug Administration (FDA). In addition, he was responsible for development of global regulatory strategies for IND and NDA submissions. Dr. Ryan was also involved in business development activities and served as the lead regulatory officer for the due diligence team for PharmaBio, which is the corporate ventures group of Quintiles. Prior to joining Quintiles, Dr. Ryan served as Director, Regulatory and Scientific Affairs at PPD, Inc. He also served in various preclinical and clinical positions of increasing responsibility at F. Hoffman-La Roche, Ltd., Pfizer, Inc. and at Bristol-Myers Squibb, Inc.

Dr. Ryan received his Ph.D. in Toxicology from the University of North Carolina and also earned M.S. degrees in Pharmacokinetics and Genetics from North Dakota State University. In addition, Dr. Ryan is a Diplomate of the American Board of Toxicology.

### **About AtheroGenics**

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The company has four drug development programs in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III clinical trial called ARISE, as an oral therapy for the treatment of atherosclerosis. AGIX-4207, the Company's second clinical compound derived from its proprietary v-protectant(tm) technology platform, is a novel, oral agent being tested in a Phase II clinical program called OSCAR, for the treatment of rheumatoid arthritis. AGIX-4207 I.V. is an intravenous rheumatoid arthritis treatment that has completed a Phase I clinical study. AGI-1096 is a novel, oral agent that is being developed for the prevention of organ transplant rejection in collaboration with Fujisawa. For more information about AtheroGenics, please visit <http://www.atherogenics.com>

*This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. These risks include statements which address operating performance, events or developments that we expect or anticipate will occur in the future, such as projections about our future results of operations or our financial condition, research, development and commercialization of our product candidates, anticipated trends in our business, and other risks that could cause actual results to differ materially. These risks are discussed in AtheroGenics' Securities and Exchange Commission filings, including but not limited to the risks discussed in AtheroGenics' Form 10-K for fiscal 2003.*

Donna Glaskv

Corporate Communications  
678-336-2517  
[investor@atherogenics.com](mailto:investor@atherogenics.com)

Investor Relations  
Lilian Stern  
Stern Investor Relations  
212-362-1200  
[lilian@sternir.com](mailto:lilian@sternir.com)

Media Relations  
Katie Brazel  
Fleishman Hillard  
404-739-0150  
[brazelk@fleishman.com](mailto:brazelk@fleishman.com)

<http://www.atherogenics.com>